Correlation between conjunctival provocation test (CPT) and systemic allergometric tests in allergic conjunctivitis.

Regional Centre for the Diagnosis and the Treatment of Inflammatory Eye Diseases, University of Padova, Italy.
Eye (Impact Factor: 1.9). 02/1990; 4 ( Pt 5):760-4. DOI: 10.1038/eye.1990.109
Source: PubMed

ABSTRACT In order to assess the potential usefulness of CPT as a diagnostic tool for ocular allergy, the correlation between skin/RAST tests and CPT was determined in 144 patients affected by allergic 'hay fever' type conjunctivitis. The results showed that an agreement between skin/RAST tests and CPT occurred in 71% of the cases (130/183). Of the 29% uncorrelated cases, 23% (43/183) were positive for at least one specific antigen by skin/RAST tests but not by CPT, while 6% (10/183) were positive for at least one specific antigen by CPT, but not by skin/RAST tests. CPT dramatically increased the histamine levels in tears (p less than 0.001). These findings show that (1) systemic tests can be misleading in that they may suggest a specific sensitisation which, in fact, does not involve the conjunctiva (systemic test positive/CPT negative); (2) CPT can identify local conjunctival sensitisation in the absence of a systemic sensitisation (systemic test negative/CPT positive); (3) CPT can demonstrate that allergic 'hay fever' type conjunctivitis may be related to allergens different from those responsible for a systemic sensitisation.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Allergic conjunctivitis, unlike many ocular conditions, is rarely associated with permanent visual impairment. It is, however, a common and extremely uncomfortable problem for those who are affected. Because patients with allergic conjunctivitis may be seen by the allergist and the ophthalmologist, it is important for both to recognize the hallmarks of allergic conjunctivitis and to understand the different therapeutic alternatives for the management of this condition.
    Immunology and Allergy Clinics of North America 02/1997; 17(19-1):19-&. DOI:10.1016/S0889-8561(05)70288-5 · 2.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: No parameters currently exist that can reliably predict the impact of preseasonal immunotherapy on the symptoms occurring during the season. The purpose of our studies was to prove a correlation between preseasonal conjunctival allergen challenge and coseasonal primary clinical endpoints using the total combined score, ie, a combination of symptoms and medication score, as the primary outcome parameter. Twelve weeks before both the birch and the grass pollen seasons, 2 separate prospective, double-blind, randomized, controlled studies were conducted followed by posttrial observations for each study during the active season. In the studies, patients who reacted to conjunctival allergen challenge were treated with sublingual immunotherapy tablets that contain either birch and/or alder or grass pollen allergoids. In all, 158 patients were included in the grass and 160 in the tree pollen study; of these, 100 and 109 patients, respectively, took part in the posttrial observations. When comparing patients with and without a positive reaction in the final conjunctival allergen challenge, the results revealed a significant difference in the total combined score (grass: P < .001; birch: P = .039). The same applied to the rescue medication score (P = .005; P = .025). A significant difference regarding the rhinoconjunctivitis symptom score was shown in the grass pollen study (P = .002), and the difference of well days was significant in the tree pollen study (P = .049). When comparing patients based on their reaction to allergen challenge after immunotherapy, each study leads to similarly significant results. Therefore, conjunctival allergen challenge can be used effectively as a parameter to predict allergic rhinoconjunctivitis symptoms during the season in patients treated with preseasonal sublingual immunotherapy tablets. Whether this can be transferred to untreated patients needs to be determined. Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
    01/2015; DOI:10.1016/j.jaip.2014.10.015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Allergic conjunctivitis is common, especially during the allergy season. Consultation with the allergist to perform skin tests or in vitro tests may be useful and confirmatory in the diagnosis of ocular allergy. If treatment is necessary, antihistamines, mast cell stabilizers, and nonsteroidal anti-inflammatory drugs are safe and reasonably effective. Corticosteroids are an order of magnitude more potent than noncorticosteroids; however, they have attendant side effects that are best monitored by the ophthalmologist. The development of "modified" corticosteroids has been a boon to the treatment of ocular allergy because these drugs may reduce potential side effects without sacrificing potency.
    Immunology and Allergy Clinics of North America 03/2008; 28(1):43-58, vi. DOI:10.1016/j.iac.2007.12.005 · 2.22 Impact Factor